Sonke-Lamivudine+Zidovudine 150 mg, 300 mg FC tablets
PDF Leaflet Revision Date: 21 November 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV infection in adults and children over 12 years.
Dosage (summary)
One tablet twice daily.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Not recommended during pregnancy; avoid breastfeeding.
Key Drug Interactions
- Avoid with ribavirin and stavudine
- Caution with trimethoprim
Contraindications
- Hypersensitivity to components
- Low neutrophil or hemoglobin counts
- Children under 12 years
Common side effects
- Neutropenia
- Anaemia
- Nausea
- Fatigue
- Rash
Counselling Points
- Monitor for signs of lactic acidosis
- Avoid alcohol
- Adhere to dosing schedule
Serious warnings
- Risk of lactic acidosis
- Hepatotoxicity
- Immune reconstitution inflammatory syndrome
Important Disclaimer
The Sonke-Lamivudine+Zidovudine 150 mg, 300 mg FC tablets professional information leaflet below is the property of Ranbaxy Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
